-+ 0.00%
-+ 0.00%
-+ 0.00%

Barclays Maintains Overweight on Cytokinetics, Raises Price Target to $110

Benzinga·08/13/2026 18:09:10
Listen to the news
Barclays analyst Emily Field maintains Cytokinetics (NASDAQ:CYTK) with a Overweight and raises the price target from $95 to $110.